BROTIZOLAM

'Brotizolam' (marketed under brand name Lendormin) is a drug which is thienobenzodiazepine (a benzodiazepine derivative). It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties, and is considered to be similar in effect to short-acting benzodiazepines such as triazolam. It is used in the short term treatment of insomnia although due to its short half life it is considered to have relatively high abuse potential and so would not be a first-line treatment. Brotizolam is a potent drug with a dosage of between 0.5 and 1.5 milligrams, but is rapidly eliminated with an average half life of 4.4 hours (range 3.6 - 7.9 hours).
Brotizolam is not approved for sale in the United States or Canada.

Contents

References

External links

References

★ Greenblatt DJ, Locniskar A, Shader RI. ''Pilot pharmacokinetic study of brotizolam, a thienodiazepine hypnotic, using electron-capture gas-liquid chromatography.'' Sleep. 1983;6(1):72-6. PMID 6844800.

★ Langley MS, Clissold SP. ''Brotizolam. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an hypnotic.'' Drugs. 1988 Feb;35(2):104-22.

★ Bechtel WD. ''Pharmacokinetics and metabolism of brotizolam in humans.'' British Journal of Clinical Pharmacology. 1983;16 Suppl 2:279S-283S.

★ Jochemsen R. ''Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration.'' British Journal of Clinical Pharmacology. 1983;16 Suppl 2:285S-290S.

External links

★ Inchem.org - Brotizolam